Immunosuppression therapy for pediatric heart transplantation

Area of Science:

• Pediatric Cardiology
• Transplantation Immunology
• Pharmacogenomics

Background:

• Pediatric cardiac transplantation outcomes have improved, largely due to advances in immunosuppressive therapy.
• Current immunosuppression management in children lacks evidence-based randomized controlled trials, relying on clinical experience and registry data.

Purpose of the Study:

• To review trends in pediatric thoracic transplant immunosuppression and outcomes.
• To highlight the impact of pharmacogenomics, evolving drug choices, and the move towards personalized immunosuppression.

Main Methods:

• Analysis of trends from large pediatric transplant registries.
• Review of evolving immunosuppressive drug regimens, including induction therapy, maintenance agents, and adjunctive therapies.
• Examination of the role of pharmacogenomics and anti-HLA antibodies.

Main Results:

• Increased use of induction therapy and tacrolimus over cyclosporine.
• Mycophenolate mofetil (MMF) is increasingly used, replacing azathioprine.
• Steroid avoidance is associated with excellent outcomes; mTOR inhibitors are not yet widely established.
• Growing recognition of anti-HLA antibodies' role in adverse outcomes.

Conclusions:

• Individualized immunosuppressive therapy, guided by biomarkers, is the future of pediatric transplantation.
• Pharmacogenomics and targeted therapies offer potential for improved graft and patient survival.
• The "one size fits all" approach to immunosuppression is obsolete.